Qihua Zou
State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.
Journal: Biomarker research
Published: May 14, 2026
Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell Lymphoma.
Journal: American journal of hematology
Published: February 05, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.
Journal: Nature communications
Published: December 24, 2025
Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study.
Journal: Blood cancer journal
Published: September 25, 2025
A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction.
Journal: Cell reports. Medicine
Published: September 01, 2025
Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications.
Journal: Nature communications
Published: July 07, 2025
TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial.
Journal: Med (New York, N.Y.)
Published: May 08, 2025
Heat shock factor 1 promotes proliferation and chemoresistance in diffuse large B-cell lymphoma by enhancing the cell cycle and DNA repair.
Journal: Cell death & disease
Published: January 11, 2025
Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial.
Journal: Cancer medicine
Published: November 22, 2024
Nomogram for predicting the prognosis of metastatic thymic epithelial tumors.
Journal: Journal of thoracic disease
Published: October 27, 2024
Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial.
Journal: BMC medicine
Published: May 07, 2024
Last Updated: 09/26/2026